Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
Marie WislezJulien MazieresArmelle LavoleGérard ZalcmanOlivier CarreThomas EgenodRaffaele CaliandroCatherine Dubos-ArvisGaelle JeanninOlivier MolinierMarie-Ange MassianiAlexandra LanglaisFranck MorinFrancoise Le Pimpec BarthesLaurent BrouchetJalal AssouadBernard MilleronDiane DamotteMartine AntoineVirginie WesteelPublished in: Journal for immunotherapy of cancer (2022)
Neoadjuvant durvalumab given as monotherapy was associated with an 89% complete resection rate and an MPR of 19%. Despite an unexpectedly high rate of postoperative deaths, which prevented us from completing the trial, we were able to show a significant association between MPR and DFS.
Keyphrases
- locally advanced
- rectal cancer
- lymph node
- squamous cell carcinoma
- small cell lung cancer
- radiation therapy
- patients undergoing
- phase iii
- open label
- study protocol
- clinical trial
- phase ii
- combination therapy
- advanced non small cell lung cancer
- randomized controlled trial
- brain metastases
- liver metastases
- epidermal growth factor receptor
- tyrosine kinase